Metastatic NSCLC

Oncology

19 drugs in development·9 companies·2 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
Cyramza	ELI LILLY & Co (LLY)
Cyramza®	ELI LILLY & Co (LLY)
docetaxel	Amneal Pharmaceuticals, Inc. (AMRX)
krazati	BRISTOL MYERS SQUIBB CO (BMY)
krazati	Mirati Therapeutics, Inc. (MRTX)
opdivo qvantig	BRISTOL MYERS SQUIBB CO (BMY)

Phase 3(7)

Phase 2(4)

Phase 1(2)

Drug	Company
acasunlimab	Genmab A/S (GMAB)
amg 510	AMGEN INC (AMGN)

BioSniper tracks 19 drugs in development for Metastatic NSCLC across 9 companies.

There are 2 clinical trials targeting Metastatic NSCLC tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.